MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2

被引:59
作者
Wang, Guannan [1 ]
Fang, Xiaosan [2 ]
Han, Meng [2 ]
Wang, Xiaoming [2 ]
Huang, Qiang [1 ]
机构
[1] Anhui Med Univ, Anhui Prov Hosp, Dept Pancreatobiliary Surg, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China
[2] Yijishan Hosp, Wannan Med Coll, Dept Hepatobiliary Surg, Wuhu 241001, Anhui, Peoples R China
关键词
hepatocellular carcinoma; miR-493-5p; vesicle associated membrane protein 2; apoptosis; invasion; HEPATOCELLULAR-CARCINOMA CELLS; GASTRIC-CANCER; EXPRESSION; METASTASIS; OUTCOMES; THERAPY;
D O I
10.3892/ijmm.2018.3358
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the present study was to explore the role of miR-493-5p in liver cancer tissues and cell lines, and its effect on cell behavioral characteristics. The expression of miR-493-5p was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in liver cancer tissues and cell lines (hepatic cell line HL-7702 and the liver cancer cell lines HCCC-9810, HuH-7 and HepG2). In addition, the mechanism by which miR-493-5p mediates its effects was analyzed via the transfection of miR-493-5p mimic and negative control miRNA into HepG2 cells. The viability, proliferation, apoptosis and invasion of the cells were analyzed using MTT assay, flow cytometry and Transwell chamber experiments. Furthermore, the effect of miR-493-5p on the expression of vesicle associated membrane protein 2 (VAMP2) was assayed using a dual-luciferase reporter system, and VAMP2 protein levels were determined by western blot analysis. In addition, following the cotransfection of HepG2 cells with pcDNA3.1-VAMP2 plasmid and miR-493-5p mimic, the role of miR-493-5p as a regulator of VAMP2 was evaluated using MTT assay, flow cytometry and Transwell chamber experiments. RT-qPCR analysis indicated that the expression of miR-493-5p in liver cancer tissues and cell lines was decreased significantly compared with that in adjacent normal liver tissues and normal liver cell lines, respectively. Compared with the control group, the cells transfected with miR-493-5p mimic (the miR-493-5p overexpression group) exhibited reduced cell viability, a reduced percentage of cells in the S phase and an increased percentage of apoptotic cells. In addition, fewer cells passed through the Transwell membrane in the miR-493-5p overexpression group compared with the control group. In the dual-luciferase reporter assay, luciferase activity in the miR-493-5p overexpression group was attenuated compared with that in the control group. In addition, western blot analysis indicated that the VAMP2 protein levels in the miR-493-5p overexpression group were lower than those in the control group. Furthermore, in cells overexpressing miR-493-5p and VAMP2 simultaneously, the biological behavior of the cells, including cell viability, cell cycle and cell invasiveness, was significantly rescued compared with that of the control group transfected with miR-493-5p alone. In conclusion, miR-493-5p is indicated to be a tumor suppressor gene, and is downregulated in human liver cancer. miR-493-5p overexpression promotes cell apoptosis and inhibits the proliferation and migration of liver cancer cells by negatively regulating the expression of VAMP. These observations suggest the potential of treating liver cancer by the overexpression of microRNA-493-5p.
引用
收藏
页码:1740 / 1748
页数:9
相关论文
共 56 条
[1]   Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma [J].
Afonso, Marta B. ;
Rodrigues, Pedro M. ;
Simao, Andre L. ;
Castro, Rui E. .
JOURNAL OF CLINICAL MEDICINE, 2016, 5 (03)
[2]   Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States [J].
Altekruse, Sean F. ;
Henley, S. Jane ;
Cucinelli, James E. ;
McGlynn, Katherine A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) :542-553
[3]  
[Anonymous], 2017, BIOTARGET, DOI DOI 10.21037/BIOTARGET.2017.05.02
[4]  
D'Costa N, 2017, BIOTARGET, V1, P3
[5]  
Fang Q, 2017, BIOTARGET, V1, P6, DOI DOI 10.21037/BIOTARGET.2017.05.01
[6]   Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence [J].
Gao, Jian-zhi ;
Li, Jia ;
Du, Jing-li ;
Li, Xiao-lei .
ONCOLOGY LETTERS, 2016, 11 (03) :1791-1798
[7]   RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases [J].
Gonzalez-Rodriguez, Agueda ;
Valverde, Angela M. .
CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (31) :4574-4586
[8]   A genomic case study of mixed fibrolamellar hepatocellular carcinoma [J].
Griffith, O. L. ;
Griffith, M. ;
Krysiak, K. ;
Magrini, V. ;
Ramu, A. ;
Skidmore, Z. L. ;
Kunisaki, J. ;
Austin, R. ;
McGrath, S. ;
Zhang, J. ;
Demeter, R. ;
Graves, T. ;
Eldred, J. M. ;
Walker, J. ;
Larson, D. E. ;
Maher, C. A. ;
Lin, Y. ;
Chapman, W. ;
Mahadevan, A. ;
Miksad, R. ;
Nasser, I. ;
Hanto, D. W. ;
Mardis, E. R. .
ANNALS OF ONCOLOGY, 2016, 27 (06) :1148-1154
[9]   Characterization of VAMP2 in Schistosoma japonicum and the Evaluation of Protective Efficacy Induced by Recombinant SjVAMP2 in Mice [J].
Han, Qian ;
Hong, Yang ;
Fu, Zhiqiang ;
Zhang, Min ;
Cao, Xiaodan ;
Liu, Yantao ;
Ma, Shuai ;
Guo, Yuntao ;
Lu, Ke ;
Zhu, Chuangang ;
Lin, Jiaojiao .
PLOS ONE, 2015, 10 (12)
[10]   Development and novel therapeutics in hepatocellular carcinoma: a review [J].
Ingle, Pravinkumar Vishwanath ;
Samsudin, Sarah Zakiah ;
Chan, Pei Qi ;
Ng, Mei Kei ;
Heng, Li Xuan ;
Yap, Siu Ching ;
Chai, Amy Siaw Hui ;
Wong, Audrey San Ying .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 :445-455